Skip to Main Content

Author Details

Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
2004
143
42
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37984849Drug combinations screening using a Bayesian ranking approach based on dose-response models.Biom J2024
36327154Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.Blood2023
36951151Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience.Haematologica2023
37424223Novel precision medicine approaches and treatment strategies in hematological malignancies.J Intern Med2023
37085611UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.Leukemia2023
37205853LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.Blood Adv2023
36773040Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis.Ann Hematol2023
36455187Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.J Clin Oncol2023
36630200Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis.Blood Cancer Discov2023
34756112Semen Cryopreservation in Adolescents and Young Adults with Hematologic Diseases: from Bed to Benchside.J Adolesc Young Adult Oncol2022
35443031Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.Blood2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
35797337Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications.PLoS One2022
35668193P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.Nat Cancer2022
35667047Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis.Blood2022
35523579Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms.J Am Soc Nephrol2022
35750691A multiparametric niche-like drug screening platform in acute myeloid leukemia.Blood Cancer J2022
36570694Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively.Hemasphere2022
36494771Publisher Correction: Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r.BMC Bioinformatics2022
36307762Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r.BMC Bioinformatics2022
35984904Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation.Blood2022
35947955Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.Cell Rep2022
36153475The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.BMC Cancer2022
36151081Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML.Blood Cancer J2022
35148910Endothelial cells: major players in acute myeloid leukaemia.Blood Rev2022
35115654Macrophage migration inhibitory factor is overproduced through EGR1 in TET2<sup>low</sup> resting monocytes.Commun Biol2022
34615986Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.Leukemia2022
32581253Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.Leukemia2021
33881523Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.Blood2021
33623140Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.Leukemia2021
33564086Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.Leukemia2021
33690800Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.Blood2021
34410352Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.Blood2021
34638371Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias.Cancers (Basel)2021
34301789Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy.Cancer Discov2021
34344988Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease.Leukemia2021
33299234Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.Haematologica2021
33043739Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.Leuk Lymphoma2021
32871585A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.Blood2021
31171638Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.Haematologica2020
32100599Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.Leuk Lymphoma2020
31710255Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis.Leuk Lymphoma2020
33054132Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.Haematologica2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
32119970Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?Biol Blood Marrow Transplant2020
32380535Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.Blood Adv2020
32203462Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.Nat Genet2020
32460980Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?Best Pract Res Clin Haematol2020
32132655Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.Leukemia2020
32344427CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia.Blood2020
  • 1 - 50 of 143

Recommended Authors

Curtis A Lachowiez
University of Texas MD Anderson Cancer Center
Career Start Year 2017
Number of shared co-authors 3
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Career Start Year 2014
Number of shared co-authors 9
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 2
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Career Start Year 2010
Number of shared co-authors 6
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 14
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Uma Borate
The Ohio State University
Career Start Year 2008
Number of shared co-authors 7
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 14
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 19
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 6
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 10
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 2
Naseema Gangat
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 8
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 11
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 7
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 3
Gudrun G??hring
Hannover Medical School
Career Start Year 2002
Number of shared co-authors 7
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 3
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 10
Rafael Bejar
Moores Cancer Center, university of california san diego
Career Start Year 2001
Number of shared co-authors 9
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 7
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 8
Lucy A Godley
The University of Chicago
Career Start Year 1994
Number of shared co-authors 18
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 0
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 13
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 8
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 12
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 22
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 31

Collaborators

Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Co-authored papers 52
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Co-authored papers 31
Emmanuel Raffoux
Universite Paris Diderot
Co-authored papers 30
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 29
Claude Gardin
Avicenne Hospital
Co-authored papers 23
Emmanuelle Clappier
Saint-Louis Hospital
Co-authored papers 19
Matthieu Duchmann
Assistance Publique-Hopitaux de Paris, Universite de Paris
Co-authored papers 18
Thorsten Braun
Centre Hospitalier Universitaire Hopital Avicenne
Co-authored papers 16
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Co-authored papers 15
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 14
Jean Soulier
University of Paris
Co-authored papers 12
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Co-authored papers 10
Luca Malcovati
University of Pavia & S. Matteo Hospital
Co-authored papers 8
Reinaldo Dal Bello
Universite Paris Cite, INSERM, CNRS
Co-authored papers 6
Cl??mentine Chauvel
Universite Paris Cite, INSERM, CNRS
Co-authored papers 5
Anna Raimbault
CHU La Miletrie University Hospital Poitiers France.
Co-authored papers 5
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 5
Antoine Forget (CM4AI)
University of California San Francisco
Co-authored papers 4
Daniel Birnbaum
Co-authored papers 4
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 4
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Co-authored papers 4
Jeannig Berrou
Universite Paris Cite, Institut de Recherche Saint-Louis
Co-authored papers 4
Gaetano Sodaro
Universite Paris Cite, INSERM, CNRS
Co-authored papers 4
Kris C Wood
Duke University
Co-authored papers 3
Angela Su
The Broad Institute of MIT and Harvard
Co-authored papers 3
Gabriela Alexe
Dana-Farber Cancer Institute
Co-authored papers 3
Elie Azoulay
Paris Cite University
Co-authored papers 3
Kevin H Lin
Duke University
Co-authored papers 3
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 3
Justine Penneroux
Universite Paris Cite, INSERM, CNRS
Co-authored papers 3
Release 1.2